Abstract:Signal
transducer and activator of transcription 3 (STAT3) is an
attractive cancer therapeutic target. We report herein our extensive in vitro and in vivo evaluations of SD-91,
the product of the hydrolysis of our previously reported STAT3 degrader
SD-36. SD-91 binds to STAT3 protein with a high affinity and displays
>300-fold selectivity over other STAT family protein members. SD-91
potently and effectively induces degradation of STAT3 protein and
displays a high selectivity over other STAT members and >7000 … Show more
“…In subsequent studies, they found that SD-36 hydrolyzed and converted its difluoro methylene group to a ketone group under different conditions in vitro and in vivo , and the conversion rate in an alkaline environment was much faster than that in acidic conditions. 184 After confirming the conversion mechanism, they tested the degradation activity of the converted degrader SD-91 (Fig. 15), and found that the degrader SD-91 showed excellent stability in different drug delivery systems.…”
Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.
“…In subsequent studies, they found that SD-36 hydrolyzed and converted its difluoro methylene group to a ketone group under different conditions in vitro and in vivo , and the conversion rate in an alkaline environment was much faster than that in acidic conditions. 184 After confirming the conversion mechanism, they tested the degradation activity of the converted degrader SD-91 (Fig. 15), and found that the degrader SD-91 showed excellent stability in different drug delivery systems.…”
Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.
This review highlights important milestones in the evolution of PROTACs, briefly discusses recent lessons about targeted protein degradation, and conjectures on the efforts still needed to expand the toolbox for PROTAC discovery.
“…In our previous study, we showed that an indole-based phosphotyrosine mimetic was critical for our development of potent and cell-permeable STAT3 degraders . However, the indole-based phosphotyrosine mimetic was later found to have a chemical stability issue where difluoro carbon moiety in the indole-based phosphotyrosine mimetic gradually decomposes to form ketone . To overcome this issue, we carried out extensive modification of the indole-based phosphotyrosine mimetic and identified other phosphotyrosine mimetics with excellent chemical stability, including a benzothiophene-based phosphotyrosine mimetic .…”
STAT5 is an attractive therapeutic
target for human cancers. We
report herein the discovery of a potent and selective STAT5 degrader
with strong antitumor activity in vivo. We first
obtained small-molecule ligands with sub-micromolar to low micromolar
binding affinities to STAT5 and STAT6 SH2 domains and determined co-crystal
structures of three such ligands in complex with STAT5A. We successfully
transformed these ligands into potent and selective STAT5 degraders
using the PROTAC technology with AK-2292 as the best compound. AK-2292
effectively induces degradation of STAT5A, STAT5B, and phosphorylated
STAT5 proteins in a concentration- and time-dependent manner in acute
myeloid leukemia (AML) cell lines and demonstrates excellent degradation
selectivity for STAT5 over all other STAT members. It exerts potent
and specific cell growth inhibitory activity in AML cell lines with
high levels of phosphorylated STAT5. AK-2292 effectively reduces STAT5
protein in vivo and achieves strong antitumor activity
in mice at well-tolerated dose schedules.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.